Related Experiment Videos
[The prevention of liver disease in the hemophilic child]
Insights
Hepatitis B vaccination and heat-treated clotting factors can reduce the risk of post-transfusion hepatitis (PTH) in children with hemophilia. These interventions are crucial for preventing viral infections and their long-term complications in this vulnerable population.
Area of Science:
- Pediatric Hematology
- Infectious Diseases
- Transfusion Medicine
Background:
- Modern replacement therapy for hemophilia has improved management of inherited bleeding disorders in children.
- Early treatments using plasma-derived clotting factors expose hemophiliacs to blood-borne viruses, leading to post-transfusion hepatitis (PTH).
- High prevalence of hepatitis B virus, non-A, non-B agents, and delta agent infections is documented in children with hemophilia.
Purpose of the Study:
- To analyze current surveillance measures for reducing PTH risk in young hemophilic patients.
- To evaluate preventive strategies for viral infections in hemophilic children.
Main Methods:
- Review of existing surveillance and prevention strategies for post-transfusion hepatitis.
- Analysis of the efficacy of hepatitis B vaccination in susceptible children.
- Assessment of the use of heat-treated antihemophilic factor to reduce infectivity.
Main Results:
- Hepatitis B vaccination is a significant preventive measure for susceptible children.
- Heat-treated clotting factors can reduce infectivity in previously untreated children without active viral infections.
- These strategies aim to mitigate the risk of viral transmission and subsequent health issues.
Conclusions:
- Hepatitis B vaccination and the use of heat-treated clotting factors are key interventions.
- Implementing these measures can significantly decrease the incidence of PTH in hemophilic children.
- Proactive prevention is essential for improving long-term health outcomes in children with hemophilia.
Abstract:
The modern replacement therapy of inherited bleeding disorders has proved to be a major advance in the management of haemophilic children. However, the haemophiliacs, early treated with commercial clotting factor concentrates obtained from large amounts of plasma, are exposed to blood borne viruses responsible for post-transfusion hepatitis (PTH) and for their possible harmful long-term sequelae. Infact high prevalence of infection with hepatitis B virus, non-A, non-B agents, delta agent has been documented among haemophilic children. In this study we analyze the measures of surveillance at present available in order to reduce the risk of PTH in young haemophilic patients. Among these measures of prevention we point out the magnitude of administrating hepatitis B vaccine to susceptible children and of using antihaemophilic factor heat-treated to reduce infectivity in those children who have never been treated and without signs of active viral infections.